Mergers and Acquisitions
1,540+ M&A transactions for an aggregate value of $745+ billion since 2019
Why Cooley
-
180+ member team in 19 major business and technology centers in the US, Europe and Asia
-
Broad industry platform with clients across many industries and sophisticated capabilities in all practice areas
-
Excel in deals in the tech, life sciences, artificial intelligence, medical device and healthcare, consumer, education, defense and media industries
-
Given our market position in the medtech and life sciences sectors, we have handled a large number of life sciences M&A transactions, both public and private, and understand unique structuring issues for life sciences companies, including milestone structures, contingent value rights and option structures
-
Primary corporate counsel to 250+ public companies, giving us an unmatched perspective on market deal points and ability to facilitate introductions between buyers and sellers
-
Represent all categories of participants in transactions, including buyers, sellers, major stockholders, venture capitalists, lenders, financial advisors, management/founders, special board committees, individual investors, private equity funds, hedge funds and others
-
Adept at handling all manner of transactions, including domestic and cross-border mergers and acquisitions, strategic deals including joint ventures, acquisitions of IP assets, patent cross-licenses, complex divestitures and spin-offs, takeover defense and shareholder activism counseling, and multibillion-dollar public company mergers
-
Robust SPAC experience and thought leaders in the area with a repository of market insight and guidance for businesses interested in the IPO alternative @ SPACtivity
-
Market-leading IP, privacy, technology licensing, life sciences collaborations and licensing, regulatory, government contracts, credit finance, private equity, antitrust, employment, compensation and tax practices to support transactions
M&A Blog
Newsworthy developments in the global mergers and acquisitions space
Public Company Innovation Hub
Resources for forward-thinking board members and leaders of US-listed public companies
Recognition
- Chambers: Ranked Band 1 for USA - Nationwide Corporate/M&A: Highly Regarded
- Bloomberg: #2 for Global and US M&A by Deal Count (2023)
- Bloomberg: #3 for UK M&A by Deal Count (2023)
- Bloomberg: #1 for Global and US Mid-market M&A by Deal Count (2023)
- Bloomberg: #2 for Global and US Mid-market M&A by Deal Value (2023)
- Mergermarket: Top 5 for Global M&A by Deal Count (2023)
- Mergermarket: Top 4 for US M&A by Deal Count (2023)
- LSEG: Top 3 for Global Completed M&A by Deal Count (2023)
- LSEG: Top 2 for US Completed M&A by Deal Count (2023)
- LSEG: #2 for US Target Announced and Completed M&A by Deal Count (2023)
- LMG Life Sciences: M&A Firm of the Year (2023)
Global Business Hub
Resources for US companies to launch and succeed in new global markets
Group contacts
